Abstract: An oral sustained-release pharmaceutical composition of indapamide and a process for producing the foregoing pharmaceutical composition are provided. The pharmaceutical composition comprises indapamide in an amount between 0.2% and 4% (w/w) of the composition, a hydrophilic polymer in an amount between 10 % and 30% (w/w) of the composition, a dry binding agent in an amount between 2% and 20% (w/w) of the composition, and an erosion modifier in an amount between 40% and 80% (w/w) of the composition. The sustained-release pharmaceutical composition of indapamide could be obtained at lower expenditure and produced in a safe and economical manner.

Abstract: The present invention relates to an oral sustained-release pharmaceutical composition of indapamide and a process for producing the foregoing pharmaceutical composition. The pharmaceutical composition comprises indapamide in the amount 0.2% to 4% (w/w) of the composition, a hydrophilic polymer in the amount 10% to 30% (w/w) of the composition, a dry binding agent in the amount 2% to 20% (w/w) of the composition, and an erosion modifier in the amount 40% to 80% (w/w) of the composition. The present invention also relates to a method for delivering indapamide to a patient in need of indapamide-related therapies, which comprises administering to the patient a therapeutically effective amount of a sustained-release pharmaceutical composition in accordance with the present invention.